Informations générales (source: ClinicalTrials.gov)

NCT04076748 Statut inconnu
Evaluation of the Efficacy of Intra-nasal Sufentanil for Analgesia of Vaso-occlusive Crisis in Sickle-cell Adults. (DREPSUFINDOL)
Interventional
Phase 3
University Hospital, Bordeaux (Voir sur ClinicalTrials)
juillet 2021
janvier 2024
08 mars 2025
The analgesic treatment for vaso-occlusive crisis (VOC) in sickle-cell patients is an emergency. The reference treatment is morphine, which requires a venous way sometimes difficult to obtain in these patients. Sufentanil intranasal has been shown to be effective in traumatology. The objective is to evaluate, in VOC, the efficacy of intranasal sufentanil relayed by morphine IV compared to the usual protocol, Equimolar Mixture of Oxygen-Nitrous Oxide (EMONO) relayed by morphine intravenous (IV).
 Voir le détail

Etablissements

Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
AP-HP - Hôpital Louis Mourier Nicolas JAVAUD Recrutement non commencé Contact (sur clinicalTrials)
CENTRE HOSPITALIER DE GONESSE Mustapha YOUSSEF En recrutement IDF Contact (sur clinicalTrials)
Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
Hôpital Charles Nicolle - 76031 - Rouen - France Luc-Marie JOLY, Pr Recrutement non commencé Contact (sur clinicalTrials)
Hopital Pellegrin - 33000 - Bordeaux - France Michel GALINSKI, Pr En recrutement Contact (sur clinicalTrials)
Hôpital Rangueil - 31059 - Toulouse - France Annie MOMO BONA En recrutement Contact (sur clinicalTrials)
Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
Hôpital Edouard Herriot - 69003 - Lyon - France Virginie LVOVSCHI En recrutement Contact (sur clinicalTrials)

Critères

Tous
Inclusion Criteria:

- Age 18 to 75 years old;

- Sickle-cell patient.

- Signs of a vaso-occlusive crisis (migratory bone pain, which may occur in the limbs,
spine, thorax, pelvis, skull) or crisis known as such by the patient;

- Severe pain (NRS ≥ 6/10) on admission to the ED;

- Registered with the social security scheme or his beneficiaries (except AME)

- Signature of free and informed consen.



- Strong opioids received in the previous 6 hours;

- Pregnancy or breastfeeding;

- Woman not menopausal nor sterile without effective contraception (HAS criteria)

- Oxygen saturation below 93%;

- Patients who cannot cooperate because of a State of agitation or a Cognitive
impairment

- Unable to communicate;

- Unable to do self-assessment;

- Allergy or intolerance to opiates or nitrous oxide.

- Abuse or addiction to opioids

- Liver insufficiency

- Renal insufficiency

- Severe asthma or chronic obstructive bronchopulmonary disease

- Pulmonary disease necessitating oxygen

- Presence of seriousness signs:

- All respiratory seriousness signs

- all neurologic signs or consciousness impairment (coma Glasgow scale under 15)

- hyperthermia over than 39°C

- Signs of intolerance of acute anemia

- Signs of hemodynamic failure

- Known organ failure (renal insufficiency, pulmonary high blood pressure)

- A description by the patient of a non usual crisis.

- Current treatment with nasal vasoconstrictors is ongoing

- Head injury with suspicion of high intracranial pressure

- Severe thoracic trauma or decompensated respiratory insufficiency

- Contraindications of intranasal administration:

- Facial trauma

- Nose or sinusal surgery in the previous 6 months before inclusion

- Chronic nose and upper airway alteration (ex. facial malformation)

- Acute nose and upper airway alteration (ex. Epistaxis, acute respiratory
infection, sinusitis).

- Contraindication to nitrous oxide

- Contraindication to morphine

- Patient's refusal to participate in the study.

- Previous inclusion in the study of less than 14 days.